Suppression of transforming growth factor-β effects in rabbit subconjunctival fibroblasts by activin receptor-like kinase 5 inhibitor

Molecular Vision

Volumn 16, Issue , 2010, Pages 1880-1892

  Sapitro, Jennifer ^a   Dunmire, Jeffrey J ^a   Scott, Sarah E ^a   Sutariya, Vijay ^b   Geldenhuys, Werner J ^b   Hewit, Michael ^b   Yue, Beatrice Y J T ^c   Nakamura, Hiroshi ^a,b  

^a SUMMA HEALTH SYSTEM   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; ALPHA SMOOTH MUSCLE ACTIN; CONNECTIVE TISSUE GROWTH FACTOR; HISTIDINE; MITOMYCIN C; SB 505124; SERINE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL INFILTRATION; CONJUNCTIVA; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; HISTOPATHOLOGY; HYDROGEN BOND; INTRAOCULAR PRESSURE; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; SCAR FORMATION;

ACTINS; ANIMALS; BENZODIOXOLES; BINDING SITES; BIOLOGICAL ASSAY; BLOTTING, WESTERN; CELL COUNT; CONJUNCTIVA; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLASTS; FILTERING SURGERY; FLUORESCENT ANTIBODY TECHNIQUE; GLAUCOMA; IMIDAZOLES; INTRAOCULAR PRESSURE; MODELS, MOLECULAR; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RABBITS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA2;

EID: 77956968913     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A. Transforming growth factor-β. Cancer Surv 1992; 12:81-103.
2. Piek E, Heldin CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999; 13:2105-2124.
3. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331:1286-1292.
4. Massagué J. TGF-β signal transduction. Annu Rev Biochem 1998; 67:753-791.
5. Massagué J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000; 1:169-178.
6. Connor TB Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM. Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest 1989; 83:1661-1666.
7. McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-β treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999; 163:5693-5699.
8. Shah M, Foreman DM, Ferguson MW. Neutralisation of TGFβ1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J Cell Sci 1995; 108:985-1002.
9. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 1999; 40:705-712.
10. Hales AM, Chamberlain CG, McAvoy JW. Cataract induction in lenses cultured with transforming growth factor-β. Invest Ophthalmol Vis Sci 1995; 36:1709-1713.
11. Chen C, Michelini-Norris B, Stevens S, Rowsey J, Ren X, Goldstein M, Schultz G. Measurement of mRNAs for TGFβ and extracellular matrix proteins in corneas of rats after PRK. Invest Ophthalmol Vis Sci 2000; 41:4108-4116.
12. He S, Jin ML, Worpel V, Hinton DR. A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization. Arch Ophthalmol 2003; 121:1283-1288.
13. Yamanaka R, Ogata N, Yamamoto C, Matsushita M, Matsuzaki K, Uyama M, Matsumura M. Expression of transforming growth factor-β receptors in normal rat retina and experimental choroidal neovascularization. Jpn J Ophthalmol 2002; 46:525-532.
14. Cordeiro MF. Role of transforming growth factor beta in conjunctival scarring. Clin Sci (Lond) 2003; 104:181-187.
15. Cordeiro MF. Beyond Mitomycin: TGF-β and wound healing. Prog Retin Eye Res 2002; 21:75-89.
16. Jampel HD, Roche N, Stark WJ, Roberts AB. Transforming growth factor-β in human aqueous humor. Curr Eye Res 1990; 9:963-969.
17. Saika S, Yamanaka O, Baba Y, Kawashima Y, Shirai K, Miyamoto T, Okada Y, Ohnishi Y, Ooshima A. Accumulation of latent transforming growth factor-beta binding protein-1 and TGF β1 in extracellular matrix of filtering bleb and of cultured human subconjunctival fibroblasts. Graefes Arch Clin Exp Ophthalmol 2001; 239:234-241.
18. Migdal C, Gregory W, Hitchings R. Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma. Ophthalmology 1994; 101:1651-1656.
19. Addicks EM, Quigley HA, Green WR, Robin AL. Histologic characteristics of filtering blebs in glaucomatous eyes. Arch Ophthalmol 1983; 101:795-798.
20. Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S. Prolonged localized tissue effects from 5-minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol 1993; 111:263-267.
21. Cordeiro MF, Reichel MB, Gay JA, D'Esposita F, Alexander RA, Khaw PT. Transforming growth factor-β1, -β2, and -β3 in vivo: effects on normal and mitomycin C-modulated conjunctival scarring. Invest Ophthalmol Vis Sci 1999; 40:1975-1982.
22. Crowston JG, Akbar AN, Constable PH, Occleston NL, Daniels JT, Khaw PT. Antimetabolite-induced apoptosis in Tenon's capsule fibroblasts. Invest Ophthalmol Vis Sci 1998; 39:449-454.
23. Stamper RL, McMenemy MG, Lieberman MF. Hypotonous maculopathy after trabeculectomy with subconjunctival 5-fluorouracil. Am J Ophthalmol 1992; 114:544-553.
24. Cordeiro MF, Gay JA, Khaw PT. Human anti-transforming growth factor-β2 antibody: a new glaucoma anti-scarring agent. Invest Ophthalmol Vis Sci 1999; 40:2225-2234.
25. Mead AL, Wong TT, Cordeiro MF, Anderson IK, Khaw PT. Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery. Invest Ophthalmol Vis Sci 2003; 44:3394-3401.
26. Cordeiro MF, Mead A, Ali RR, Alexander RA, Murray S, Chen C, York-Defalco C, Dean NM, Schultz GS, Khaw PT. Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome. Gene Ther 2003; 10:59-71.
27. Nakamura H, Siddiqui SS, Shen X, Malik AB, Pulido JS, Kumar NM, Yue BY. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol Vis 2004; 10:703-711.
28. CAT-152 0102 Trabeculectomy Study Group. Khaw P, Grehn F, Holló G, Overton B, Wilson R, Vogel R, Smith Z. A phase III study of subconjunctival human anti-transforming growth factor β(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmology 2007; 114:1822-1830.
29. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1:727-730.
30. Swinney DC. Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov 2004; 3:801-808.
31. Piek E, Roberts AB. Suppressor and oncogenic roles of transforming growth factor-β and its signaling pathways in tumorigenesis. Adv Cancer Res 2001; 83:1-54.
32. Byfield SD, Roberts AB. Lateral signaling enhances TGF-β response complexity. Trends Cell Biol 2004; 14:107-111.
33. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003; 113:685-700.
34. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA. Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542. Mol Pharmacol 2002; 62:58-64.
35. Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ. Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5). J Med Chem 2002; 45:999-1001.
36. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith EC, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM. Synthesis and activity of new aryland heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domain. J Med Chem 2003; 46:3953-3956.
37. DaCosta Byfield S, Major C, Laping NJ, Roberts AB. SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2004; 65:744-752.
38. Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors. J Med Chem 2004; 47:4494-4506.
39. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M. SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64:7954-7961.
40. Tojo M, Hamashima Y, Hanyu A, Kajimoto T, Saitoh M, Miyazono K, Node M, Imamura T. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-tomesenchymal transition by transforming growth factor-β. Cancer Sci 2005; 96:791-800.
41. Xiao YQ, Liu K, Shen JF, Xu GT, Ye W. SB-431542 inhibition of scar formation after filtration surgery and its potential mechanism. Invest Ophthalmol Vis Sci 2009; 50:1698-1706.
42. Yue BY, Baum JL. Studies of corneas in vivo and in vitro. Vision Res 1981; 21:41-43.
43. Olmo IG, Ghaly ES. Compressional characterization of two dextrose-based directly compressible excipients using an instrumented tablet press. Pharm Dev Technol 1999; 4:221-231.
44. Khaw PT, Doyle JW, Sherwood MB, Grierson I, Schultz G, McGorray S. Prolonged localized tissue effects from 5- minute exposures to fluorouracil and mitomycin C. Arch Ophthalmol 1993; 111:263-267.
45. Gellibert F, Woolven J, Fouchet MH, Mathews N, Goodland H, Lovegrove V, Laroze A, Nguyen VL, Sautet S, Wang R, Janson C, Smith W, Krysa G, Boullay V, De Gouville AC, Huet S, Hartley D. Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors. J Med Chem 2004; 47:4494-4506.
46. Yingling JM, Blanchard KL, Sawyer JS. Development of TGFbeta signaling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3:1011-1022.
47. Li X, Wang L, Long L, Xiao J, Hu Y, Li S. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor β type 1 receptor (ALK5). Bioorg Med Chem Lett 2009; 19:4868-4872.
48. Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 2005; 313:943-951.